Avidity Partners Management LP - Q4 2016 holdings

Add to watchlist

All
New
Buy
Sell
Exit
Unchanged
 Value Shares↓ Weighting
No holdings reported for quarter Q4 2016
Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
NEUROCRINE BIOSCIENCES INC18Q2 20244.6%
ARVINAS INC17Q2 20244.9%
SYNDAX PHARMACEUTICALS INC17Q2 20243.2%
NATERA INC16Q2 20243.5%
IDEAYA BIOSCIENCES INC16Q2 20242.5%
ABBVIE INC15Q2 20249.7%
AVANTOR INC14Q2 20246.0%
ZENTALIS PHARMACEUTICALS INC14Q3 20234.8%
IMMUNOCORE HLDGS PLC14Q2 20242.0%
ALPINE IMMUNE SCIENCES INC14Q1 20241.5%

View Avidity Partners Management LP's complete holdings history.

Latest significant ownerships (13-D/G)
Avidity Partners Management LP Q4 2016 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Context Therapeutics Inc.May 13, 20247,500,4319.9%
ARCA biopharma, Inc.April 09, 20241,000,0006.9%
Jasper Therapeutics, Inc.March 27, 2024760,0005.1%
Altimmune, Inc.Sold outFebruary 14, 202400.0%
IDEAYA Biosciences, Inc.February 14, 20241,520,0002.4%
Karyopharm Therapeutics Inc.February 14, 202411,188,7439.5%
Kezar Life Sciences, Inc.February 14, 20245,025,4546.9%
Akero Therapeutics, Inc.February 13, 2024235,0000.4%
ARVINAS, INC.February 13, 20242,985,1174.4%
Cyteir Therapeutics, Inc.Sold outFebruary 13, 202400.0%

View Avidity Partners Management LP's complete significant-ownership history.

Latest filings
TypeFiled
N-PX2024-08-30
13F-HR2024-08-14
13F-HR2024-05-15
SC 13G2024-05-13
SC 13G2024-04-09
SC 13G2024-03-27
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Avidity Partners Management LP's complete filings history.

All filings

View complete filings history.

Compare quarters

Export Avidity Partners Management LP's holdings

CSVXLS